Effectiveness of omega-3 fatty acids in the management of hypertriglyceridemia: a multi-centre retrospective study

Ajitkumar A. Gondane; Pooja H. Vaidya; Dattatray B. Pawar; Akhilesh D. Sharma

doi:10.18203/2320-6012.ijrms20260609

Authors

Ajitkumar A. Gondane Medical Affairs Division, Alkem Laboratories, Mumbai, India
Pooja H. Vaidya Medical Affairs Division, Alkem Laboratories, Mumbai, India
Dattatray B. Pawar Medical Affairs Division, Alkem Laboratories, Mumbai, India
Akhilesh D. Sharma Medical Division, Alkem Laboratories, Mumbai, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20260609

Keywords:

Cardiovascular, Cholesterol, Docosahexaenoic acid, Eicosapentaenoic acid, Triglycerides

Abstract

Background: Hypertriglyceridemia is increasingly prevalent in India and represents a major contributor to atherosclerotic cardiovascular disease and overall cardiometabolic risk. Although large global trials have demonstrated the triglyceride-lowering efficacy of Omega-3 fatty acids (O3FA), real-world evidence regarding their effectiveness, safety, and prescribing patterns in the Indian population remains scarce. This study aimed to evaluate the real-world effectiveness, safety, and utilization patterns of O3FA therapy in Indian patients with hypertriglyceridemia.

Methods: This retrospective, multicentre observational study analyzed medical records of patients diagnosed with hypertriglyceridemia who were prescribed O3FA between January 2023 and April 2024 across multiple healthcare centers in India. Demographic details, treatment duration, lipid parameters, glycemic indices, and adverse events were assessed.

Results: A total of 447 patient records were included in the analysis. The majority were male (80.3%), with a mean age of 49.5 years. Patients received one O3FA capsule daily for a mean duration of 2.09 months. Statistically significant and clinically meaningful improvements were observed in lipid parameters: triglycerides decreased by 113.42 mg/dl, total cholesterol by 75.99 mg/dl, LDL-C by 49.15 mg/dl, and VLDL by 13.99 mg/dl, while HDL-C increased by 16.47 mg/dl (p<0.001 for all). Glycemic control also improved, with reductions in fasting blood glucose (−24.79 mg/dl), postprandial glucose (−10.17 mg/dl), and HbA1c (−0.94%). Only four patients reported mild gastrointestinal adverse events, and no serious adverse events were documented.

Conclusions: O3FA therapy demonstrated significant improvements in lipid and glycemic parameters with an excellent safety profile, reinforcing its role as an effective and well-tolerated cardiometabolic intervention in routine Indian clinical practice.

Metrics

Metrics Loading ...

References

Mehra P, Mehta V, Yusuf J, Safal, Dabla PK. Cardiovascular disease epidemic in India and triglyceride-associated residual atherosclerotic cardiovascular disease risk. APFCB News. 2024;3(1):69–78. DOI: https://doi.org/10.62772/APFCB-News.2024.1.1

Anjana RM, Unnikrishnan R, Deepa M, Pradeepa R. ICMR-INDIAB Collaborative Study Group. Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17). Lancet Diabetes Endocrinol. 2023;11(7):474-89. DOI: https://doi.org/10.1016/S2213-8587(23)00119-5

Gupta R, Guptha S, Agrawal A, Kaul V, Gaur K, Gupta VP. Secular trends in cholesterol lipoproteins and triglycerides and prevalence of dyslipidemias in an urban Indian population. Lipids Health Dis. 2008;7:40. DOI: https://doi.org/10.1186/1476-511X-7-40

National Institute of Nutrition (NIN), Indian Council of Medical Research (ICMR). CNNS v1.0 Data Note for MoHFW. Hyderabad: National Institute of Nutrition;. Available at: https://healthnutritionindia.in/reports/documents. Accessed on 21 August 2025.

Zimodro JM, Rizzo M, Gouni-Berthold I. Current and Emerging Treatment Options for Hypertriglyceridemia: State-of-the-Art Review. Pharmaceuticals (Basel). 2025;18(2):147. DOI: https://doi.org/10.3390/ph18020147

Oh RC, Trivette ET, Westerfield KL. Management of Hypertriglyceridemia: Common Questions and Answers. Am Fam Physician. 2020 Sep 15;102(6):347-54.

Kris-Etherton PM, Harris WS, Appel LJ; American Heart Association. Nutrition Committee. Fish consumption, fish oil, omega-3 fatty acids, and cardiovascular disease. Circulation. 2002;106(21):2747-57. DOI: https://doi.org/10.1161/01.CIR.0000038493.65177.94

Liu QK. Triglyceride-lowering and anti-inflammatory mechanisms of omega-3 polyunsaturated fatty acids for atherosclerotic cardiovascular risk reduction. J Clin Lipidol. 2021;15(4):556-68. DOI: https://doi.org/10.1016/j.jacl.2021.05.007

Skulas-Ray AC, Wilson PWF, Harris WS, Brinton EA. American Heart Association Council on arteriosclerosis, thrombosis and vascular biology; council on lifestyle and cardiometabolic health; council on cardiovascular disease in the young; council on cardiovascular and stroke nursing; and council on clinical cardiology. omega-3 fatty acids for the management of hypertriglyceridemia: a science advisory from the American Heart Association. Circulation. 2019;140(12):673-91. DOI: https://doi.org/10.1161/CIR.0000000000000709

Kastelein JJ, Maki KC, Susekov A, Ezhov M. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. J Clin Lipidol. 2014;8(1):94-106. DOI: https://doi.org/10.1016/j.jacl.2013.10.003

IBM SPSS Software. Available at: https://www.ibm.com/products/spss. Accessed on 21 August 2025.

Microsoft Office. 2019. Previous Version | Microsoft 365 Available at: https://www.microsoft.com/en-in/microsoft-365/previous-versions/microsoft-office. Accessed on 21 July 2025.

Gupta R, Rao RS, Misra A, Sharma SK. Recent trends in epidemiology of dyslipidemias in India. Indian Heart J. 2017;69(3):382-392. DOI: https://doi.org/10.1016/j.ihj.2017.02.020

Bornfeldt KE. Triglyceride lowering by omega-3 fatty acids: a mechanism mediated by N-acyl taurines. J Clin Invest. 2021 Mar 15;131(6):857. DOI: https://doi.org/10.1172/JCI147558

Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019;380(1):11-22. DOI: https://doi.org/10.1056/NEJMoa1812792

Yokoyama M, Origasa H, Matsuzaki M. Japan EPA lipid intervention study (JELIS) Investigators. Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet. 2007;369(9567):1090-8. DOI: https://doi.org/10.1016/S0140-6736(07)60527-3

Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). Am J Cardiol. 2012;110(7):984-92. DOI: https://doi.org/10.1016/j.amjcard.2012.05.031

Prasad M, Krishnan NS, Arun A. An update on the role of omega-3 fatty acids in metabolic health and insulin resistance: a narrative review. Texila Int J Public Health. 2024;2:4-16.